title: Single versus repeated doses of ivermectin and diethylcarbamazine for the treatment of Wuchereria bancrofti var. pacifica microfilaremia. Results at 12 months of a double-blind study.
abstract: In October 1989, 58 apparently healthy Polynesian Wuchereria bancrofti carriers in whom microfilarial (mf) density was greater than or equal to 100 mf/ml were randomly allocated to treatment groups receiving single doses of either ivermectin at 100 mcg/kg or diethylcarbamazine (DEC) at 3 and 6 mg/kg. Six months later, half of the carriers initially treated with ivermectin 100 mcg/kg or DEC 3 mg/kg were given a second similar dose while the rest were given a placebo. By day 360 (6 months after retreatment), comparison of adjusted geometric mean mf counts per group indicated that (i) among the 3 treatments given once a year the DEC 6 mg/kg dose resulted in the highest efficacy, (ii) nevertheless, regarding either ivermectin 100 mcg/kg or DEC 3 mg/kg, 2 successive doses resulted in higher efficacy than one annual dose and (iii) though no significant difference could be evidenced between efficacy of ivermectin 100 mcg/kg and DEC 3 mg/kg given twice a year, DEC seemed to sustain the mf reduction for a longer period of time. During the 3 days following retreatment, adverse reactions (mild to moderate) were observed in 46% of carriers treated with microfilaricidal drugs and in 20% of those treated with placebo. These results suggest that single dose therapy with either DEC or ivermectin is safe and effective for prevention of lymphatic filariasis due to Wuchereria bancrofti in French Polynesia. The real impact on transmission by the vector, Aedes polynesiensis, of the complete negativation of microfilaremia observed during the previous part of the trial in carriers treated with ivermectin should be evaluated in a community-based trial including entomological study.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti, Polynesie Francaise.
authors.forename: J L
authors.initials: JL
authors.lastname: Cartel
authors.forename: A
authors.initials: A
authors.lastname: Spiegel
authors.forename: L
authors.initials: L
authors.lastname: Nguyen Ngnoc
authors.forename: R
authors.initials: R
authors.lastname: Cardines
authors.forename: R
authors.initials: R
authors.lastname: Plichart
authors.forename: P M
authors.initials: PM
authors.lastname: Martin
authors.forename: J F
authors.initials: JF
authors.lastname: Roux
mesh_terms: D000328:Adult; D000818:Animals; D002353:Carrier State / Q000188:drug therapy*; D004049:Diethylcarbamazine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004605:Elephantiasis, Filarial / Q000188:drug therapy*; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008842:Microfilariae / Q000187:drug effects; D008875:Middle Aged; D014958:Wuchereria bancrofti / Q000187:drug effects*
chemical_list: D007559:Ivermectin; D004049:Diethylcarbamazine